Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Payables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Payables for 11 consecutive years, with $20.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 38.82% to $20.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Dec 2025, up 38.82% year-over-year, with the annual reading at $20.3 million for FY2025, 38.82% up from the prior year.
  • Payables for Q4 2025 was $20.3 million at Intellia Therapeutics, up from $13.3 million in the prior quarter.
  • The five-year high for Payables was $20.3 million in Q4 2025, with the low at $3.6 million in Q3 2023.
  • Average Payables over 5 years is $10.3 million, with a median of $9.7 million recorded in 2021.
  • The sharpest move saw Payables skyrocketed 97814.29% in 2021, then crashed 47.91% in 2025.
  • Over 5 years, Payables stood at $9.7 million in 2021, then plummeted by 46.61% to $5.2 million in 2022, then soared by 44.59% to $7.5 million in 2023, then surged by 95.77% to $14.6 million in 2024, then skyrocketed by 38.82% to $20.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $20.3 million, $13.3 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.